Moteur de recherche d’entreprises européennes
Financement de l’UE (2 626 200 €) : Programme de formation européen pour comprendre, diagnostiquer et traiter les maladies rétiniennes autosomiques dominantes Hor11/07/2023 Programme de recherche et d'innovation de l'UE « Horizon »
Vue d’ensemble
Texte
Programme de formation européen pour comprendre, diagnostiquer et traiter les maladies rétiniennes autosomiques dominantes
ProgRET will create a multidisciplinary and intersectoral European training network focusing on the mechanisms, diagnosis and therapy of dominantly inherited retinal diseases (IRD). IRD represent a major cause of blindness, affecting 350,000 people in Europe. IRD have long been considered incurable, however major advances have led to groundbreaking new treatments. Today, the most important challenges in the IRD field relate to an unsolved genetic diagnosis, unknown disease mechanisms and gene therapy development for autosomal dominant IRD (adIRD), representing 25–40% of all IRD cases. We have demonstrated an emerging role for splicing factors, structural variants and non-coding defects in patients with adIRD, and developed novel disease models and gene therapies for adIRD. ProgRET aims to dissect adIRD mechanisms using retinal stem cell and aquatic animal models, to advance adIRD diagnostics using a single-molecule multi-omics framework, and to develop innovative treatments based on RNA therapy and CRISPR-genome editing. These challenges will be tackled by integrating unique expertise and cutting-edge technology within ProgRET, including (multi-)omics, bioinformatics, functional genomics, RNA biology, gene regulation, stem cell technology, retinal organoids, animal models, genome editing and gene therapy. ProgRET will give Doctoral Candidates (DCs) unparalleled training opportunities in outstanding academic and industrial settings through training-by-research via individual research projects, secondments, and network-wide training sessions. All individual training and research activities will provide each DC with the necessary skills in academic and industrial research. ProgRET will make a career in both sectors attractive and improve their career prospects. Finally, our multidisciplinary network offers a unique opportunity to accelerate the understanding, diagnostics and therapeutics for adIRD in Europe, and to translate research findings to healthcare and society.
| Fighting Blindness | ? |
| Agencia Estatal Consejo Superior de Investigaciones Cientificas | 251 971 € |
| EBERHARD KARLS UNIVERSITAET TUEBINGEN | 260 539 € |
| EVOTEC INTERNATIONAL GmbH | 260 539 € |
| Fondazione Telethon ETS | 259 438 € |
| Institut National de la Sante et de la Recherche Medicale | 282 694 € |
| STICHTING RADBOUD UNIVERSITAIR MEDISCH CENTRUM | 548 741 € |
| Universiteit Gent | 525 240 € |
| Ustav Molekularni Genetiky AV CR V.V.I. | 237 038 € |
https://cordis.europa.eu/project/id/101120562
Cette annonce se réfère à une date antérieure et ne reflète pas nécessairement l’état actuel. L’état actuel est présenté à la page suivante : Fighting Blindness, Dublin, Irlande.
